Date: October 13, 2021
Time: 11:00 am—3:00 pm ET
A persistent challenge in the field of immunotherapy is the fact that only a minority of patients respond, especially those therapies that rely on immune activation such as checkpoint inhibitors due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, the development of robust biomarkers, enabling rational patient selection and the design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment.
This complimentary, half-day virtual event will address critical issues around biomarker development, including:
- How do we identify optimal biomarkers for the Drug Discovery/Development pipeline?
- How to implement digital pathology strategies in Immunotherapy Clinical Trials?
- How best to bridge translational research and clinical pathology?
This half day event is about embracing not just the power of digital pathology but importantly the value of partnerships and end to end workflows to better serve the scientific community.
Marilyn Bui, MD, PhD, FCAP
Scientific Director of Analytic Microscopy Core
Moffitt Cancer Center & Research Institute
Travis Hollman, MD, PhD
Director, Advanced Immunomorphology Platforms
Memorial Sloan Kettering Cancer Center
Prof. Dr. Josef Rüschoff
Chief Medical Officer
Targos, A Discovery Life Sciences Company
Anthony Magliocco, MD
Pathologist and Prof. of Oncology and Pathology
Protean Diagnostics
Produced with support from:
